U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N
Molecular Weight 149.2328
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENTERMINE

SMILES

CC(C)(N)CC1=CC=CC=C1

InChI

InChIKey=DHHVAGZRUROJKS-UHFFFAOYSA-N
InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C10H15N
Molecular Weight 149.2328
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html

Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse. Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. Phentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

CNS Activity

Originator

Approval Year

1959
143
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 0.31 µM [EC50]
Inhibitor
8504
 498.0 µM [Ki]
Inhibitor
8504
 375.0 µM [Ki]
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ADIPEX-P

Approved Use

ADIPEX-P® is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors

Launch Date

1958
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
44.78 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25668796
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
49.1 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2057.33 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25668796
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2000 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.63 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25668796
7.5 mg single, oral
dose: 7.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TOPIRAMATE
TOPIRAMATE
 PHENTERMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Other AEs: Abdominal pain, Dizziness...
Other AEs:
Abdominal pain (6%)
Dizziness (6%)
Early satiety (6%)
Intermittent headache (6%)
Nausea (6%)
Swollen lips (6%)
Upper respiratory infection (6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Other AEs: Anorexia, Back pain...
Other AEs:
Anorexia (6%)
Back pain (6%)
Chapped lips (6%)
Dry skin (6%)
Dyspepsia (6%)
Early satiety (6%)
Irregular pulse (6%)
Nausea (6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Other AEs: Tachycardia, Hypertension...
Other AEs:
Tachycardia
Hypertension
Visual disorders NEC
Nausea
Insomnia
Anxiety
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Disc. AE: Amnesia, Judgement impaired...
Other AEs: Disorder sleep, Depression...
AEs leading to
discontinuation/dose reduction:
Amnesia (0.3%)
Judgement impaired (0.3%)
Memory impairment (0.3%)
Paraesthesia (0.3%)
Depression (1%)
Anxiety (0.3%)
Vision blurred (0.3%)
Eye pain (0.3%)
Abdominal pain (0.3%)
Tuberculosis skin test positive (0.3%)
Nephrolithiasis (0.3%)
Other AEs:
Disorder sleep (12.9%)
Depression (8.1%)
Anxiety (9.5%)
Cardiac arrhythmia (4.1%)
Ischemic heart disease (1%)
Disturbance in attention (3.1%)
Memory impairment (2%)
Cognitive disorders (1.4%)
Language disorder (0.3%)
Ocular disorders NEC (4.1%)
Dyskinesias and movement disorders NEC (1.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Dizziness 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Early satiety 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Intermittent headache 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Nausea 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Swollen lips 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Upper respiratory infection 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Anorexia 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Back pain 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Chapped lips 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Dry skin 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Dyspepsia 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Early satiety 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Irregular pulse 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Nausea 6%
37.5 mg 1 times / day single, oral
Recommended
Dose: 37.5 mg, 1 times / day
Route: oral
Route: single
Dose: 37.5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
healthy, 18 - 45 years old
Health Status: healthy
Age Group: 18 - 45 years old
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf
Anxiety
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Hypertension
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Insomnia
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Nausea
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Tachycardia
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Visual disorders NEC
390 mg 1 times / day single, oral
Studied dose
Dose: 390 mg, 1 times / day
Route: oral
Route: single
Dose: 390 mg, 1 times / day
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
healthy, mean age 30 years
Health Status: healthy
Age Group: mean age 30 years
Sex: M+F
Sources:
https://www.koreascience.or.kr/article/JAKO201429638663634.pdf
Language disorder 0.3%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Abdominal pain 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Amnesia 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Anxiety 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Eye pain 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Judgement impaired 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Memory impairment 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Nephrolithiasis 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Paraesthesia 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Tuberculosis skin test positive 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Vision blurred 0.3%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Ischemic heart disease 1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Depression 1%
Disc. AE
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Cognitive disorders 1.4%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Dyskinesias and movement disorders NEC 1.4%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Disorder sleep 12.9%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Memory impairment 2%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Disturbance in attention 3.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Cardiac arrhythmia 4.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Ocular disorders NEC 4.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Depression 8.1%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Anxiety 9.5%
15 mg 1 times / day multiple, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
unhealthy, mean age 51.9 years
Health Status: unhealthy
Age Group: mean age 51.9 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252

substrate
1946
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2E1
1060
CYP
74
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP
150
 no
CYP1A2
2333
 no
CYP2C9
2497
 no
CYP2D6
2546
 no
CYP2E1
1146
 no
CYP3A4
2633
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1946
 major
weak (co-administration study)
Comment: In the presence of topiramate, phentermine Cmax and AUC0-inf increased 13 and 42%, respectively
Page: 39,38
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:8080
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8080
eMolecules
1846375
https://www.emolecules.com/cgi-bin/more?vid=1846375
ZINC
ZINC000008403947
http://zinc15.docking.org/substances/ZINC000008403947
PubMed

PubMed

TitleDatePubMed
Acute nonarteritic ischaemic optic neuropathy after phentermine.
2005-11
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
2005-01-25
The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment.
2004-12
Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women.
2004-12
The long-term management of obesity with continuing pharmacotherapy.
2004-11
Pharmacological and surgical treatment of obesity.
2004-07
Relationship between collagen fibrils, glycosaminoglycans, and stress relaxation in mitral valve chordae tendineae.
2004-07
Taking things to heart.
2004-07
Obesity.
2004-06
Obesity: an overview on its current perspectives and treatment options.
2004-04-14
Going before disciplinary board without counsel is unwise. Case on point: Slone-Vasquez v. Kentucky Board Of Nursing, 2003 WL 22976179 S.W.3d-KY.
2004-01
Obesity.
2003-12
Do these doctors give medicine a black eye?
2003-12
Ischemic colitis after weight-loss medication.
2003-12
The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux.
2003-12
Effects of tyrosine, phentermine, caffeine D-amphetamine, and placebo on cognitive and motor performance deficits during sleep deprivation.
2003-08
A comparison of tyrosine against placebo, phentermine, caffeine, and D-amphetamine during sleep deprivation.
2003-08
Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats.
2003-07-05
Risk of valvular heart disease associated with use of fenfluramine.
2003-06-11
Effects of phentermine and phenformin on biomarkers of aging in rats.
2003-05-14
National trends in antiobesity medication use.
2003-05-12
Malpractice. Conviction upheld for doctor who treated AIDS with fen/phen.
2003-05-09
Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.
2003-04
Anorexigen-induced cardiac valvulopathy and female gender.
2003-04
Noradrenergic modulation of ephedrine-induced hypophagia.
2003-04
Postmarketing surveillance of abuse liability of sibutramine.
2003-03-01
Medical monitoring for pharmaceutical injuries: tort law for the public's health?
2003-02-19
Obesity drug pipeline not so fat.
2003-02-07
Internet pharmacy prescription and phentermine overdose.
2003-02
Treatment of obesity: an update on anti-obesity medications.
2003-02
Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography.
2002-12-01
Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
2002-12
Pharmacological management of obesity.
2002-12
Enantiomeric separation of methamphetamine and related analogs by capillary zone electrophoresis: intelligence study in routine methamphetamine seizures.
2002-11
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion?
2002-10-04
Diet medications and valvular heart disease: the current evidence.
2002-09-21
Appetite suppressants and valvular heart disease.
2002-09
Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects.
2002-09
Appetite suppressants and valvular heart disease - a systematic review.
2002-08-23
Fen-Phen-noumenon: A mass tort litigation and settlement about to come and go.
2002-08
Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
2002-06-15
Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine.
2002-06-07
Reversal of Phen-Fen associated valvular regurgitation documented by serial echocardiography.
2002-06
I have tried everything I can think of to lose weight on my own and am now thinking of using weight-loss medications. Are they safe?
2002-05
Prevalence of drug use in commercial tractor-trailer drivers.
2002-05
Regression and progression of valvulopathy associated with fenfluramine and phentermine.
2002-03-19
Phentermine inhibition of recombinant human liver monoamine oxidases A and B.
2002-03-01
Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine.
2002-03
Automated headspace solid-phase microextraction and in-matrix derivatization for the determination of amphetamine-related drugs in human urine by gas chromatography-mass spectrometry.
2002-01
Pharmacotherapy of obesity: currently marketed and upcoming agents.
2002
Patents

Patents

05536714
5
05698720
5
05808071
2
06376555
2
JP2001172180A
3
JP2005531585A
20

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Weight Loss 15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast. Usual Pediatric Dose for Weight Loss 17 years or older: 15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Route of Administration: Oral
In Vitro Use Guide
Phentermine inhibited serotonin-metabolizing (MAO-A) activity in rat lung, brain, and liver with K(i) values of 85-88 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:36:25 GMT 2025
Edited
by admin
on Mon Mar 31 17:36:25 GMT 2025
Record UNII
C045TQL4WP
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
PHENTERMINE
HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
DUROMINE
Preferred Name English
PHENTERMINE [VANDF]
Common Name English
NSC-759163
Code English
PHENTERMINE [HSDB]
Common Name English
QSIVA
Brand Name English
Phentermine [WHO-DD]
Common Name English
PHENTERMINE [MART.]
Common Name English
BENZENEETHANAMINE, .ALPHA.,.ALPHA.-DIMETHYL-
Systematic Name English
PHENTERMINE [USAN]
Common Name English
phentermine [INN]
Common Name English
PHENTERMINE [MI]
Common Name English
?,?-Dimethylphenethylamine
Systematic Name English
QSYMIA COMPONENT PHENTERMINE
Brand Name English
IONAMIN
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175651
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
WHO-VATC QA08AA01
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
NDF-RT N0000175423
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
DEA NO. 1640
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
NCI_THESAURUS C29728
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
WHO-ATC A08AA01
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
EMA ASSESSMENT REPORTS QSIVA (REFUSED: OBESITY)
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
LIVERTOX NBK548947
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
NDF-RT N0000175372
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
NDF-RT N0000175372
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
204-522-1
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
INN
1064
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
ChEMBL
CHEMBL1574
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
CHEBI
8080
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
MERCK INDEX
m8644
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY Merck Index
EVMPD
SUB09784MIG
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
HSDB
3158
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
NCI_THESAURUS
C61890
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
NSC
759163
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
WIKIPEDIA
PHENTERMINE
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
DAILYMED
C045TQL4WP
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
PUBCHEM
4771
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
RXCUI
8152
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
FDA UNII
C045TQL4WP
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
SMS_ID
100000082243
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
DRUG BANK
DB00191
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
MESH
D010645
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
CAS
122-09-8
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
IUPHAR
7269
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
DRUG CENTRAL
2140
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
EPA CompTox
DTXSID9023461
Created by admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of PHENTERMINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
AMINE OXIDASE (FLAVIN-CONTAINING) B
METABOLIC ENZYME -> INHIBITOR
PHENTERMINE RESIN COMPLEX
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
Structure of PHENTERMINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966